{
    "nctId": "NCT01492543",
    "briefTitle": "Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer",
    "officialTitle": "An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi\u00ae (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 18-75 years old female.\n* ECOG status: 0-2.\n* Life expectancy of \u2265 3 months.\n* Histologic or cytologic diagnosis of breast cancer.\n* Progression after receiving one standard prior chemotherapy regimen for recurrent or metastatic lesion except an endocrine regimen.\n* At least one measurable lesion of \\>=2 cm (\\>=1 cm on spiral CT scan)according to RECIST (v1.1).\n* Adequate organ functions:\n\n  * Hematopoietic: Hemoglobin \u226590g/L, Absolute neutrophil count \u22651.5\u00d710\\^9/L, Platelet count \u226580\u00d710\\^9/L.\n  * Biochemistry: TBil \u22641.5 times upper limit of normal (ULN), AST and ALT \u22642.5\u00d7 ULN(\u22645x ULN if due to liver metastases), Creatinine \u22641.0\u00d7ULN and Creatinine clearance \\>50 ml/min.\n* Women with children potential must have negative pregnancy tests 7 days prior to enrollment and be willing to practice acceptable methods of birth control during the study and 8 weeks after last drug administered.\n* Ability to take oral medication .\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or lactation or no effective contraception in fertile patients.\n* Prior treatment with 5-FU or drugs of same class(excluding patients that relapsed more than one year after adjuvant therapy).\n* Less than 4 weeks since prior investigational agents.\n* conditions impacting oral drug taking or absorption (e.g. inability to swallow, gastrointestinal resection, chronic diarrhea, intestinal obstruction).\n* Organ invasion with rapid progression(e.g. lesions exceeding half of Liver or Lung).\n* CNS or psychiatric disorders.\n* Allergic to 5-FU.\n* Only with bone metastases and no measurable lesions.\n* Clinically significant heart diseases (e.g.congestive heart failure, ventricular arrhythmia, myocardial infarction) before enrollment.\n* Serious peptic ulcer disease or digestive disorders.\n* Bone marrow (Hemoglobin \\<90g/dl, ANC \\<1.5\u00d710\\^9/L, Platelet count \\<75\u00d710\\^9/L).\n* Renal function disorder (Creatinine \\>1.0\u00d7ULN).\n* Liver function disorder (TBil \\>1.5\u00d7ULN).\n* Uncontrolled brain metastases.\n* Noncompliance with the study protocol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}